Aprea Therapeutics (APRE) Announces Proposed Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
February 22, 2023 4:05 PM ESTDOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (Aprea, or the Company), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced it has commenced an underwritten public offering of shares of its common stock. All shares of common stock in the offering are to be sold by Aprea. In addition, Aprea intends to grant the underwriter in the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public... More
